GSK plc’s Harvard Bioscience HBIO Stock Holding History

GSK plc’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,115	Closed	-$7.46K	–	14
2025 Q4	$7.46K	Buy	+1,115	New	+$6.61K	﹤0.01%	15

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $118M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSK plc's HBIO Position: Q1 2026 in Review

GSK plc sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 1,115 shares — an estimated $7.46K sold.

GSK plc first reported a position in HBIO in Q4 2025 and held it in 1 quarter. The position peaked at $7.46K in Q4 2025. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

GSK plc reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
GSK plc sold 1,115 Harvard Bioscience shares in Q1 2026, an estimated $7.46K.
GSK plc first reported a position in Harvard Bioscience in Q4 2025 and held it in 1 quarter.
GSK plc's Harvard Bioscience position peaked at $7.46K in Q4 2025.
37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on GSK plc's 13F filing for Q1 2026, filed 14 May 2026.